Influence of ocular residual astigmatism (ORA) in visual results after implantation of toric intraocular lenses for correcting astigmatism

Session Details

Session Title: Presented Poster Session 22: IOL Technology 1

Session Date/Time: Tuesday 16/09/2014 | 15:00-17:00

Paper Time: 15:45

Venue: Pod 1 (Poster Village)

First Author: : A.Abdelghany SPAIN

Co Author(s): :    A. Vega Estrada   P. Sanz-Díez   J. Alio   A. Plaza-Puche     

Abstract Details

Purpose:

To determine the efficacy of the astigmatism correction following toric phakic IOLs (pIOL) implantation analyzing the preoperative ORA with the Alpins vector method.

Setting:

Vissum Corporation, Alicante, Spain.

Methods:

Astigmatism was analyzed in 93 eyes of 60 patients and then divided into two groups depending on the implanted intraocular lens (IOL): ARTIFLEX group, with 50 patients and ICL Group, composed by 43 patients. Astigmatic changes were analysed using the Alpins vectorial method with the ASSORT.

Results:

Mean ORA value in each group: was 0.85 ± 0.76 in the ARTIFLEX group and 0.97 ± 0.92 in the ICL group, no significant differences between two groups, p = 0,75. In both types of lenses, the amount of refractive cylinder were significantly reduced, improving uncorrected distance visual acuity (UDVA), p<0,01. Patients with ARTIFLEX achieved a mean UDVA of 0.13 ±0.19 LogMAR, by reducing the mean refractive cylinder to -0.51 ± 0.64 D. In the ICL group, after implantation UDVA improved to 0.24 ± 0.22 LogMAR with a reduction in refractive cylinder to -1.03 ±0.79 D. Astigmatic and UDVA values were significantly better in the group with ARTIFLEX IOL than in the group implanted with ICL IOL, p <0.01. Statistical significant differences were observed in IOS between groups of IOL, p <0.01; where ARTIFLEX group presents results nearer to the ideal value. No significant correlations were found between the ORA with refractive and vectorial parameters.

Conclusions:

The ARTIFLEX and ICL toric IOLs show similar refractive results independently of the preoperative ORA value.

Financial Interest:

NONE